Literature DB >> 30543928

Relapsing Evans syndrome and systemic lupus erythematosus with antiphospholipid syndrome treated with Bortezomib in combination with plasma exchange.

Olga Tkachenko1, Sergey Lapin2, Alexey Maslyansky3, Valentina Myachikova3, Liya Mikhailova4, Boris Gilburd5.   

Abstract

Relapsing Evans syndrome (ES) and systemic lupus erythematosus (SLE) with secondary antiphospholipid syndrome (APS) is very rare association. Coexistence of these syndromes is potentially fatal and require high-dose combined immunosuppressive therapy. We describe a case of successful use of Bortezomib and plasma exchange in a patient with ES and APS refractory to standard therapy. Thirty-two-year-old male who presented episodes of relapsing hemolytic anemia, pancytopenia and multiple thrombosis with positive direct and indirect antiglobulin test result, lupus anticoagulant and medium titer of anti-beta-2-glycoprotein 1 and anti-cardiolipin antibodies was diagnosed with ES and SLE with secondary APS. High-dose therapy by steroids and Cyclosporin A were started with temporary improvement. There was also no stable improvement with Rituximab and Cyclophosphamide. Bortezomib in combination with cyclosporine A and plasma exchange was introduced. He had stable improvement in hematological parameters with no evidence of relapse of hemolytic crisis or thrombosis during a follow-up for 1 year.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Antiphospholipid syndrome; Bortezomib; Evans syndrome; Hemolysis; Thrombosis

Mesh:

Substances:

Year:  2018        PMID: 30543928     DOI: 10.1016/j.clim.2018.12.010

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  5 in total

1.  Is there a role for immunosuppression in antiphospholipid syndrome?

Authors:  Ecem Sevim; Rohan Willis; Doruk Erkan
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

2.  Plasma Exchange in a Patient with Immune Thrombocytopenia Associated with Antiphospholipid Syndrome Hospitalized for COVID-19.

Authors:  Federico Boggio; Alessandro Ciavarella; Sara Arcudi; Roberta Gualtierotti; Raffaella Rossio; Francesco Tafuri; Andrea Artoni; Flora Peyvandi
Journal:  Rheumatol Ther       Date:  2022-06-15

3.  Predictors of refractory risk in systemic lupus erythematosus-related thrombocytopenia: a dual-centre retrospective study.

Authors:  Kaisheng Su; Hao Cheng; Zhifang Jia; Yi Yuan; Huidan Yang; Qi Gao; Zhenyu Jiang; Hongyan Wen; Jing Jiang
Journal:  Lupus Sci Med       Date:  2022-05

4.  Experience of therapeutic plasma exchange in rheumatic diseases: Albumin may be a suitable substitute for plasma.

Authors:  Zhiqian Bai; Yu Chen; Lingli Dong
Journal:  Arch Rheumatol       Date:  2021-03-16       Impact factor: 1.472

5.  Combination of low-dose rituximab, bortezomib and dexamethasone for the treatment of autoimmune hemolytic anemia.

Authors:  Mingkang Yao; Jingjing Zhang; Ying Li; Linlin Lv; Lu Jia; Chunyan Yang; Yu Huang; Haihui Liu; Jian Wang; Mingtai Chen; Hao Zhang
Journal:  Medicine (Baltimore)       Date:  2022-01-28       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.